Skip to content
Screener

Innoviva, Inc. INVA Net gains (losses) on investments

Net gains (losses) on investments at other companies

Merck & Co. logo
Merck & Co.MRK
$242M+142%
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
-$22K+55.1%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$741K+123%
United Therapeutics logo
United TherapeuticsUTHR
$13.4M+435%
Option Care Health, Inc. logo
Option Care Health, Inc.OPCH
$1.7M+21.4%

Other financials

Income statement

See full
Revenue$119.6M+19.3%
Gross profit$90.6M+9.0%
Operating income$50.9M+4.3%
Net income-$83.4M-231%
EPS (diluted)-$1.14-248%

Balance sheet

See full
Cash & equivalents$570.4M+43.5%
Total debt$269.7M-40.2%
Total equity$1.2B
Total assets$1.7B+27.7%

Cash flow

See full
Operating cash flow$52.0M+17.9%
CapEx$429.0K
Free cash flow$51.5M+16.9%

Valuation

See full
Market cap$1.49B+20.6%
Enterprise value$1.19B-7.6%
P/E4.2×-27.8×
P/S3.4×+0.1×

Profitability

See full
Gross margin72.2%-10.9pp
Operating margin36.9%-10.7pp
Net margin81.2%+70.8pp
FCF margin43.1%-11.1pp

Returns & leverage

See full
Return on equity29.1%
Debt / equity0.2×
Current ratio16×+13.4×

Where this comes from

Reported directly by Innoviva, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromEquityMethodInvestments.

The source filing: Innoviva, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:26 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-335235
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Research and development5,1907,98310,43112,379
Total operating expenses39,76134,39577,44066,282
Income from operations50,85548,75189,00990,179
Changes in fair values of equity method investments, net(131,834)13,08225,816(467)
Changes in fair values of equity and long-term investments, net(29,153)11,2804,422(54,019)
Interest and dividend income7,5994,92518,5869,463
Interest expense(5,472)(4,663)(10,909)(9,374)
Other expense, net(15)(777)(381)(1,773)

Item 1. Financial Statements

FAQ

What is Innoviva, Inc.'s net gains (losses) on investments?
Innoviva, Inc. (INVA) reported net gains (losses) on investments of -$131.83M in Q2 2026.
How has Innoviva, Inc.'s net gains (losses) on investments changed year-over-year?
Innoviva, Inc.'s net gains (losses) on investments decreased by 1107.8% year-over-year, from $13.08M to -$131.83M.
What is the long-term trend for Innoviva, Inc.'s net gains (losses) on investments?
Over 3 years (2022 to 2025), Innoviva, Inc.'s net gains (losses) on investments has grown at a -4.4% compound annual growth rate (CAGR), from -$161.75M to $141.43M.
What does net gains (losses) on investments mean?
Realized and unrealized gains/losses on investments removed from operating cash flow since they're investing-related.

Ask your AI about Innoviva, Inc.'s net gains (losses) on investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude